Braidwell LP Replimune Group, Inc. Transaction History

Braidwell LP

$1.73 Billion
Q3 2025

A detailed history of Braidwell LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Braidwell LP holds 2,750,092 shares of REPL stock, worth $24.7 Million. This represents 0.66% of its overall portfolio holdings.

Number of Shares

2,750,092

Previous 422,887 550.31%

Holding current value

$24.7 Million

Previous $3.93 Million 193.33%

% of portfolio

0.66%

Previous 0.24%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.81 - $12.63 $6.54 Million - $29.4 Million	2,327,205 Added 550.31%	2,750,092 $11.5 Million
Q2 2025 Aug 14, 2025	SELL	$6.92 - $10.38 $7.19 Million - $10.8 Million	-1,038,939 Reduced 71.07%	422,887 $3.93 Million
Q1 2025 May 15, 2025	SELL	$9.75 - $14.31 $148,941 - $218,599	-15,276 Reduced 1.03%	1,461,826 $14.3 Million
Q4 2024 Feb 14, 2025	SELL	$10.54 - $14.93 $16.8 Million - $23.8 Million	-1,593,735 Reduced 51.9%	1,477,102 $17.9 Million
Q3 2024 Nov 14, 2024	BUY	$8.09 - $11.23 $16.6 Million - $23.1 Million	2,057,460 Added 203.03%	3,070,837 $33.7 Billion

Q2 2024 Aug 14, 2024	BUY	$5.01 - $9.46 $5.08 Million - $9.59 Million	1,013,377 New	1,013,377 $9.12 Billion
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $6.48 Million - $9.97 Million	413,855 Added 561.81%	487,520 $11.3 Billion
Q1 2023 May 15, 2023	SELL	$17.48 - $29.09 $10.3 Million - $17.1 Million	-588,684 Reduced 88.88%	73,665 $1.3 Billion
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $11.3 Million - $18.5 Million	662,349 New	662,349 $18 Billion

Others Institutions Holding REPL

# of Institutions

193

Shares Held

80.4M

Call Options Held

8.69M

Put Options Held

2.28M

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $443M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.

Account